Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (347 reviews)

For research use only.

Catalog No.S1065 Synonyms: RG7321

347 publications

Pictilisib (GDC-0941) Chemical Structure

CAS No. 957054-30-7

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 347 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cell Rep, 2021, 35(11):109238

PubMed: 34133937 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108750

PubMed: 33596424 ( click the link to review the publication )

Int J Cancer, 2021, 10.1002/ijc.33594

PubMed: 33844847 ( click the link to review the publication )

Cancer Lett, 2021, 510:37-47

PubMed: 33872695 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2139

PubMed: 33946744 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):619

PubMed: 34131114 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Biomolecules, 2021, 11(6)808

PubMed: 34072389 ( click the link to review the publication )
Front Oncol, 2021, 11:648985

PubMed: 34026624 ( click the link to review the publication )

Food Chem Toxicol, 2021, S0278-6915(21)00034-X

PubMed: 33484789 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):302

PubMed: 34107979 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 552:23-29

PubMed: 33740661 ( click the link to review the publication )

J Burn Care Res, 2021, irz170

PubMed: 34213565 ( click the link to review the publication )

Exp Hematol Oncol, 2021, 10(1):19

PubMed: 33663586 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Mol Cell, 2020, 80(1):164-174.e4

PubMed: 32877642 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO Mol Med, 2020, e11674

PubMed: 32558386 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(39):24427-24433

PubMed: 32929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31189-31197

PubMed: 33229547 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )

Sci Signal, 2020, 13(637):eaba8627

PubMed: 32576681 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )
Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

JCI Insight, 2020, 5(22)141832

PubMed: 33048843 ( click the link to review the publication )

Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100016

PubMed: 32984851 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4382-4392

PubMed: 32926124 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )
Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882967 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )
Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )
Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )
Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )
PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)e13441

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )
Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )
Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )
Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26384305 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )
Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )
Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )
Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MVXLbY5ie2ViQYPzZZk>		Mnv0NUBp	MYnEUXNQ	MXXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGSnbIThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	NFHr[Ys9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	MlzpT4lv[XOnIFHzd4F6		M4\zRVEhcA>?	MWnEUXNQ	NIX6SYVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEhUDFyNEetVkBufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?	NHWxc3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	NYXtbYZZU2mwYYPlJGF{e2G7		NFvSTFAyKGh?	MUXEUXNQ	M2Hw[GlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBGPTR3LVugcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0>	NG\JcXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	M37pPGtqdmG\|ZTDBd5NigQ>?		NFLWNYcyKGh?	MX;EUXNQ	MlfuTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCzN{DPxE1?	NF\uOZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	M4[2VGtqdmG\|ZTDBd5NigQ>?		MWexJIg>	M{DoTWROW09?	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGGucHjhJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjh	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
MDA-MB-361	MXrGeY5kfGmxbjDBd5NigQ>?		NUDOUY83OiCq	NVuzTFZ7TE2VTx?=	M3LPOGlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvODJ6IN88US=>	NHvYRZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
PC3	MV;GeY5kfGmxbjDBd5NigQ>?		MlTCNkBp	NX;MO5QzTE2VTx?=	MmHlTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdiCrbjDQWGVPNW63bHygbJVu[W5iUFOzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB\|NzFOwG0>	NHHJRXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
U87MG	M2e2U2Z2dmO2aX;uJGF{e2G7		NV\LfGFYOiCq	NGfVO3RFVVOR	NELtcGFKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh\|ryP	M1zQbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
MDA-MB-361	NUm4blFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4TsbVk3KGh?	M2XYNGROW09?	MljURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHerdHigVGlMO0ODIFW1OFUuUyCvdYTheIlwdiC5aYToJGlEPTBib3[gNE44OiEQvF2=	MmixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5NUS2OVQoRjF6N{W0OlU1RC:jPh?=
A2780	NYXxWlQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mo\EPVYhcA>?	NFnKe5FFVVOR	NXq5cGtrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	NV7aXmI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVQ3PTRpPkG4O\|U1PjV2PD;hQi=>
PC3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1ywOFk3KGh?	MWXEUXNQ	M3rtb2lEPTB;MD6yPEDPxE1?	M2K1WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
U87MG	NYfLV\|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVu5OkBp	NYHQSWNuTE2VTx?=	NI\vN4hKSzVyPUCuPVUh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
Sf9	NYO4dnl3U2mwYYPlJGF{e2G7		NFX0NYU{OCCvaX6=	NEXTSlRFVVOR	MVvJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiYX3veY51KG:oIFHUVEBkd26\|dX3l[EB4cXSqIFnDOVAhd2ZiMD6wOFIh\|ryP	NHzadYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0PFM1Oid-MkK1OFg{PDJ:L3G+
RAW 264.7	NUXuSlRPU2mwYYPlJGF{e2G7		NU[3dokzQTBibXnu	M2rReWROW09?	MmPOTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4zQThizszN	NUf3NmluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFg{PDJpPkKyOVQ5OzR{PD;hQi=>
Sf9	NH7KZotMcW6jc3WgRZN{[Xl?		NILuZ24yKGh?		NVH6fZZnUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2KndHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPGPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMUeg{txO	NXT5flJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDVpPkKzOVQxPjR3PD;hQi=>
Sf9	MmP6T4lv[XOnIFHzd4F6		MXmxJIg>		NFi4UHFKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\GWudHGg[ZhxemW\|c3Xk	NUm3blg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDVpPkKzOVQxPjR3PD;hQi=>
Sf9	NFHQfmdMcW6jc3WgRZN{[Xl?		NFryfVYyKGh?		NH3rbYJKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\2GvbXGg[ZhxemW\|c3Xk	M1;UZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUSwOlQ2Lz5{M{W0NFY1PTxxYU6=
Sf9	Mni3T4lv[XOnIFHzd4F6		NUToeIpIOSCq		NHnHS5BKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW\|c3Xk	NUTi[Y1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDVpPkKzOVQxPjR3PD;hQi=>
SKOV3	M4jOZmtqdmG\|ZTDBd5NigQ>?	MXqxJO69VQ>?	Mmm3NUBp	NH;HcnlFVVOR	NUS3PXdpUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbh?=	M3H3bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{[wN\|Q5Lz5{M{O2NFM1QDxxYU6=
MCF7	M2jVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXVXJZNOSEQvF2=	NGTuXWE6PiCq	MlfnSG1UVw>?	M3vuR2dKPTB;MD6wO\|AzKM7:TR?=	MlTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NkCzOFgoRjJ\|M{[wN\|Q5RC:jPh?=
SKOV3	NEHlTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXUe3FvOSEQvF2=	M37Ve\|k3KGh?	MmnGSG1UVw>?	MWfHTVUxRTBwMUS3OkDPxE1?	M2\UV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{[wN\|Q5Lz5{M{O2NFM1QDxxYU6=
PC3	M3X0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEGzdXE4OiCq	NWnGNWdQTE2VTx?=	MV;JR\|UxRTBwMkig{txO	MkXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7OEG3NVQoRjJzOUixO\|E1RC:jPh?=
MCF7.1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVjleGUxPzJiaB?=	NYrq[I4{TE2VTx?=	MnziRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BJTVJ{IHflcoUhf2m2aDDJR\|UxKG:oIECuNlgh\|ryP	NUjhU4dNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5PFE4OTRpPkKxPVgyPzF2PD;hQi=>
MCF7-neo/Her2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1TUWVczKGh?	MYTEUXNQ	MUDJR\|UxRTBwMkmg{txO	M{fQW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[yPVA{Lz5{M{[2NlkxOzxxYU6=
MCF7-neo/Her2	MUXLbY5ie2ViQYPzZZk>				MWLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDTOFc{KHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	NYPZPXczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OlI6ODNpPkKzOlYzQTB\|PD;hQi=>
PC3	NHHh[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2HoWVczKGh?	M3G3cWROW09?	NYTnc2xiTUN3ME2wMlM1KM7:TR?=	NF[4dm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4OVY{QSd-MkG5PFU3Ozl:L3G+
MCF7.1	M4LST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3ywO\|czKGh?	NFjmN4VFVVOR	MlPyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiRVO1NEBw\iByLkO5JO69VQ>?	NHXGNGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4OVY{QSd-MkG5PFU3Ozl:L3G+
PC3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIj3OZo4OiCq	NVL3bW5oTE2VTx?=	NHPTSXhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDk[YZq[2mnboSgbY4hWFSHTjD3bZRpKEmFNUCgc4YhOC5\|OTFOwG0>	NVvoPFlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwOVA3PjlpPkKwNFUxPjZ7PD;hQi=>
MCF7.1	NWfmSnVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2rKWVczKGh?	M{PYO2ROW09?	NF\ncVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDJR\|UxKG:oIECuN\|Qh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB3ME[2PUc,OjByNUC2Olk9N2F-
MCF7.1	NI\mNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4jFOlczKGh?		NYX3bYJpTUN3ME2wMlczKM7:TR?=	NIe1ZZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OlY2Pid-MkCzOFY3PTZ:L3G+
NCI-H1975	MXXDfZRwfG:6aXOgRZN{[Xl?		NWnucnhlPzJiaB?=		NEfkO2VKSzVyPUCuNlch\|ryP	NHqxO4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
H460	MWDDfZRwfG:6aXOgRZN{[Xl?		MXq3NkBp		NFrjWXhKSzVyPUCuPFch\|ryP	NH3I[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
HT-29	MXvDfZRwfG:6aXOgRZN{[Xl?		NVzXT49qPzJiaB?=		NGjadXJKSzVyPUCuOlYh\|ryP	NHPVeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
HepG2	NHq5SZdEgXSxdH;4bYMhSXO\|YYm=		M4TuOlczKGh?		NWm0cGd3UUN3ME2xJO69VQ>?	NEXIbWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
SGC7901	MU\DfZRwfG:6aXOgRZN{[Xl?		Mki1O\|IhcA>?		NEL2OHVKSzVyPUGuPEDPxE1?	NF\h[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
NCI-H226	MX;DfZRwfG:6aXOgRZN{[Xl?		MlHvO\|IhcA>?		MkflTWM2OD1{Lkmg{txO	NH25ZXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
A549	MXHDfZRwfG:6aXOgRZN{[Xl?		MkXLO\|IhcA>?		NFPHcYhKSzVyPU[uPUDPxE1?	NXTTVIV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
U87MG	NXXqOJY2S3m2b4TvfIlkKEG\|c3H5		Ml7WO\|IhcA>?		Mon0TWM2OD15Lke3JO69VQ>?	NWXkV4NXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
HBC4	M4PVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3VVotYdG:pR1m1NF0uPi5yMzDN	NEnGOlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
BSY1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TSNoxw\0eLNUC9MVYvQTBiTR?=	NI\RcIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HBC5	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjsc4dIUTVyPT22MlYxKE1?	MkK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MCF7	NYqzW49RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnlZVRtd2eJSUWwQU04NjN\|IF2=	MmDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MDA-MB-231	NWS5Z456T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnXVmNPdG:pR1m1NF0uPS52NjDN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
U251	M1\sN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXicI9oT0l3ME2tOU42OCCP	M3LtSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SF268	NYHKUZU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITac29td2eJSUWwQU02NjN7IF2=	NXqySnNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
SF295	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL5SnFJdG:pR1m1NF0uPi5\|NzDN	M2jBVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SF539	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTsc4dIUTVyPT22MlUxKE1?	NYTKTHd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
SNB75	M13vN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnsc4dIUTVyPT23MlExKE1?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SNB78	NUnxU2ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXsc4dIUTVyPT22MlUzKE1?	M3rFZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCC2998	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LIOYxw\0eLNUC9MVYvOjliTR?=	Mo\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
KM12	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mly1cI9oT0l3ME2tOU44PiCP	MkDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
HT-29	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLsc4dIUTVyPT22MlMxKE1?	NEfIV\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HCT15	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfsc4dIUTVyPT22MlEzKE1?	MkHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
HCT116	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXQTpFtd2eJSUWwQU02Njh5IF2=	MkfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
NCI-H23	NHfqPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NICwcXNtd2eJSUWwQU02Njd\|IF2=	NIHBTVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H226	NWrQV4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LBToxw\0eLNUC9MVYvOjFiTR?=	NYfq[YNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
NCI-H522	Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonhcI9oT0l3ME2tOk42QCCP	M2jn[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
NCI-H483	NED0NHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;sc4dIUTVyPT22MlU3KE1?	NF3qSXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
A549	NHj2NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7FT4hWdG:pR1m1NF0uPi5zNTDN	MmfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS273	M{\vcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MluxcI9oT0l3ME2tOk41OyCP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
DMS114	NFjwT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nDWIxw\0eLNUC9MVUvQTJiTR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
LOXIMVI	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\sc4dIUTVyPT22MlI6KE1?	M4LsXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
OVCAR3	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vI[Ixw\0eLNUC9MVYvPzFiTR?=	NHqwOnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
OVCAR4	NXLuZ3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC0cI9oT0l3ME2tOU44PiCP	MoXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLyb4tUdG:pR1m1NF0uPi5{NjDN	NX\rUlVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR8	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLLcI9oT0l3ME2tOU44OyCP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SKOV3	M4XMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3PcI9oT0l3ME2tOk42OiCP	NWL5SINLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
RXF631L	NELjXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfzcI9oT0l3ME2tOk45QCCP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
ACHN	M4PjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnsc4dIUTVyPT22MlA4KE1?	NFG5UZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
St-4	NWfPe5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4P3OIxw\0eLNUC9MVUvPTZiTR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MKN1	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPCcI9oT0l3ME2tO{4xQCCP	M{nKVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN7	NFGyd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnjcI9oT0l3ME2tOk42OCCP	NVfp[3F3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN28	M1ToPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjsc4dIUTVyPT21MlUzKE1?	NYr6fZl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN45	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHv6blJtd2eJSUWwQU03NjV3IF2=	NGPSNVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN74	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPNeGw5dG:pR1m1NF0uPi5yMjDN	MkHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DU145	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjGTmhwdG:pR1m1NF0uPS56NTDN	M4n3bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
PC3	NXfWcVN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInFZVRtd2eJSUWwQU03NjZ4IF2=	NH:4[\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
ES5	NGPm[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTVyLkKxJI5O	NU\i[IdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HH	NV3uRXoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTFzMT6wPEBvVQ>?	M2\XVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	NF3Ge45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorJTWM2OD1zMUSuN{BvVQ>?	MnHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1770	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm[wTWM2OD1zMkOuPFYhdk1?	NHTmZlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HuO9	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDDTWM2OD1{ME[uNFIhdk1?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HAL-01	MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknFTWM2OD1{ME[uO\|Mhdk1?	M{jZbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NOS-1	M3;pR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJzMT64NkBvVQ>?	NV3F[GJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HGC-27	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTJzMj61O{BvVQ>?	Mn3UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NB69	NVzielZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TteGlEPTB;MkS1MlI4KG6P	MoG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RS4-11	NF\VRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M371dmlEPTB;Mk[xMlc3KG6P	NWfEVWwzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
DOK	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFu3Z5JKSzVyPUOwNU44KG6P	M3TlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LB2241-RCC	M2SzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DET2lEPTB;M{CzMlg1KG6P	NFTGTmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H1623	M{WwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzYdXpsUUN3ME2zNFQvODhibl2=	NEnkZXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
YH-13	NGfWVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILpd21KSzVyPUOwOE4{OiCwTR?=	M1WzVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BPH-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTNzNDDuUS=>	MnnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
AN3-CA	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUf3cZhMUUN3ME2zOFAvOzdibl2=	M{LxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ES7	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPUTWM2OD1\|NEGuPVkhdk1?	NFyxUFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MDA-MB-175-VII	NHTqdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTN3Mj65NkBvVQ>?	MlTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GAMG	MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\oTWM2OD1\|N{CuPFUhdk1?	M1fLZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CHL-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkn0TWM2OD1\|N{iuOlUhdk1?	NH3NRVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NB7	M2TFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\2TVdKSzVyPUO4PU45OyCwTR?=	NX7IS2ZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MFE-280	M{nzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{m1fGlEPTB;NEG4MlIhdk1?	MlrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HL-60	NEDBUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXzTWM2OD12MkWuO\|Uhdk1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GCIY	NUXkdHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljvTWM2OD12M{OuPEBvVQ>?	NVfjSWVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MDA-MB-361	NWXYeoxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH0fVI1UUN3ME20N\|kvOTNibl2=	NV:5WYU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LXF-289	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTR2OD6yO{BvVQ>?	NGi1PZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NBsusSR	NWnsZ\|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXPcHppUUN3ME20PFgvQDVibl2=	NYPucJpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KU-19-19	NX;k[Wt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLYWlJOUUN3ME21NVYvODdibl2=	NX;aXJpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A204	NYDhNmFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTV{Mj6zN{BvVQ>?	NXfQNJgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LB1047-RCC	NGXyS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojkTWM2OD13MkKuPVMhdk1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
COLO-684	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjK[mpuUUN3ME21NlMvOTFibl2=	M2DlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
PA-1	MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TBTWlEPTB;NUOyMlQyKG6P	MnvoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MG-63	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLBTWM2OD13NEGuNVEhdk1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BHT-101	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjBb\|BMUUN3ME21OFQvQTRibl2=	NGnpWlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NKM-1	NWXDOohKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\Q[mlEPTB;NUmzMlA6KG6P	Mn;JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
T47D	NXjYTndiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1qwV2lEPTB;NUm3MlU3KG6P	NYDYcIRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MOLT-4	M1LsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2L1N2lEPTB;NkKzMlYzKG6P	NIjFWY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
IGROV-1	M3fHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\PTWM2OD14M{SuN\|Ehdk1?	NYTnWJdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ES4	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\2VWlEPTB;NkO5MlU1KG6P	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HuO-3N1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvOVoRTUUN3ME22OFIvOzhibl2=	MlTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NEC8	M3LOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzNfGpKSzVyPU[1N{42PyCwTR?=	NHjNeYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HO-1-N-1	NHHVeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\ZR2lEPTB;NkW5MlE4KG6P	NFjNWVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EPCL-272H	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTZ6Nz6yNUBvVQ>?	NYnw[lJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
D-263MG	NWPWR\|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVT1fJh{UUN3ME23NVgvOSCwTR?=	M{TWSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MV-4-11	M4PZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTd{ND6zNUBvVQ>?	NXnRWItYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-NEP-1	NF6wSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjuTWM2OD15MkWuPVQhdk1?	NUPpcI9RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW872	M3XZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3OzOGlEPTB;N{K3Mlg6KG6P	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
P30-OHK	M{PjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFW5TXhKSzVyPUezNE44OSCwTR?=	MljvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OMC-1	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\4UJIxUUN3ME23OVEvODlibl2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LoVo	NHrwPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTMWZZKSzVyPUe3O{46KG6P	NFjndW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LNCaP-Clone-FGC	NFj0b\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;OTWM2OD15OU[uN\|Qhdk1?	NF\aS2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
L-363	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jBSmlEPTB;N{m4MlQzKG6P	MoXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ES8	M1TMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYX0eFFpUUN3ME24NVAvPTJibl2=	NUnzNWFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
697	NGXib2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LTPGlEPTB;OEOxMlU2KG6P	M1Lh[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HSC-3	MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGS2R4dKSzVyPUizPU42PCCwTR?=	MnvJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
H4	NXLaZnRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTh3MD64OUBvVQ>?	MnjWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
QIMR-WIL	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\OTWM2OD16NkWuNkBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OAW-42	NWDOVnZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTh5Mj6xPUBvVQ>?	NYjLdIRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MCF7	NITHfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37YW2lEPTB;OEm4MlU6KG6P	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SCC-25	NV\tWGNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHYO2NnUUN3ME25NVQvOTlibl2=	MkHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1563	MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzTd\|NLUUN3ME25NVUvQTlibl2=	NGq4Nnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
OVCAR-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vDeGlEPTB;OUSwMlE4KG6P	NHjWS5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HDLM-2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LDWWlEPTB;OUS5MlIhdk1?	M3e3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NB5	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXYbY1KSzVyPUm1Ok43KG6P	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H292	NXvnT2xIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\BRnhTUUN3ME25O\|QvOzJibl2=	NVLyOG5qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A101D	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXSZlFKSzVyPUm5NE4yQSCwTR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1648	NU\xOWdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PxcWlEPTB;OUm4MlUyKG6P	Ml3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EKVX	NHHzU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnN[ZlvUUN3ME2xMlAyOjlizszN	NY[0VmgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW1710	NEPLU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXlbIdMUUN3ME2xMlA1OjN\|IN88US=>	NXnIfI81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
WM-115	M{fUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFwME[2OVYh\|ryP	M4f5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-54	NUH2VppOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rxPWlEPTB;MT6wO\|A5OSEQvF2=	NYLpWmJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TGBC24TKB	M4HOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DqXmlEPTB;MT6wPFA1PSEQvF2=	MofTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H520	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTUUmNKSzVyPUGuNFg6PjdizszN	M2HHfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
D-423MG	NUOwWIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\zc4hLUUN3ME2xMlA6QTZ{IN88US=>	MnjWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BFTC-905	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTFwMUO0OFkh\|ryP	NW\uNHNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HT	M3[yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TaU2lEPTB;MT6xN\|Q4QCEQvF2=	MmP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CTB-1	NIL5fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHyU2lKSzVyPUGuNVQzQTNizszN	MnTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Hs-578-T	NInaU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPObphKSzVyPUGuNVk2PjVizszN	MkXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HuH-7	M4ntb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4S3TWlEPTB;MT6yNFk1QSEQvF2=	NGHwVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LB996-RCC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTFwMkKxO\|ch\|ryP	NUjLcoRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-270	NXnKS3RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzBPYJ3UUN3ME2xMlI6PzN2IN88US=>	NYPSdG4zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A4-Fuk	NVz2U25xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\uSGlEPTB;MT6yPVk6OyEQvF2=	NFr6e5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A498	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\URnVtUUN3ME2xMlMxPDd2IN88US=>	NF\CPWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-MEL-1	NYTrd4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HGdmlEPTB;MT6zNFY4QSEQvF2=	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
AU565	NFfPVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi5TWM2OD1zLkOxPFY{KM7:TR?=	NILGUmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
Saos-2	M17Gdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTH[VVKSzVyPUGuN\|MzODVizszN	NUDoS41GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A549	MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLOfIFbUUN3ME2xMlM6QTdizszN	NYfpUG5uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BFTC-909	NESxeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvUTWM2OD1zLkSzN\|A2KM7:TR?=	M3XSd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MDA-MB-415	NFT5ZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFwNEi2PVIh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
639-V	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPZXYlKSzVyPUGuOVAzPDVizszN	NGPGfpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A704	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDubJBKSzVyPUGuOVA4QDVizszN	NUn5WVNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
PANC-03-27	NFnPWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDuTWM2OD1zLkWxOFA5KM7:TR?=	MlW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SK-MEL-28	NHuxWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUn5d5FqUUN3ME2xMlU3ODh3IN88US=>	M1nyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NUDtO25WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlO4TWM2OD1zLk[wO\|Q3KM7:TR?=	NYr3[2JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HuP-T4	M1\TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2m0b2lEPTB;MT62NFc4QCEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	NEHWVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTFwNkGyO{DPxE1?	NV7FSYxlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EFM-19	NGn0W2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TPR2lEPTB;MT62NVgyKM7:TR?=	MmLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
G-401	M1HFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjDZYNKSzVyPUGuOlIyPjRizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
D-566MG	M1zlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTFwNkK1N{DPxE1?	NUm0U5FZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
JVM-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTFwNkS4O\|Uh\|ryP	MlXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TK10	MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHncGRKSzVyPUGuOlcxQDNizszN	MlrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BT-20	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjPWZVKSzVyPUGuOlg6ODJizszN	NV7QRWI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EGI-1	M{f0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjFTVR4UUN3ME2xMlg1PzBzIN88US=>	NF3IOpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EW-16	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHyTWM2OD1zLki1NVgzKM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2228	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkj0TWM2OD1zLki1NlA{KM7:TR?=	M{TkNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BB49-HNC	NUjqe2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzlToxKSzVyPUGuPFg3QTJizszN	NXnURWdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
G-402	M3\hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFwOEm3PVch\|ryP	NVzEOok4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H526	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHGTWM2OD1zLkmxN\|kh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ME-180	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTFwOUO0O\|ch\|ryP	MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PFSK-1	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;0TWM2OD1zLkm0OFU5KM7:TR?=	NGTYUGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TYK-nu	NVnCdmNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7VTWM2OD1zLkm1PFI{KM7:TR?=	NGLVSHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HOS	M2ru[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXi4SXdMUUN3ME2xMlk4QTR6IN88US=>	M2q4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
T98G	NXm0OmVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonVTWM2OD1zLkm5NFA3KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SK-MES-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXhUHNKSzVyPUKuNFE{OzJizszN	NWHIS2wyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SNB75	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLp[HR3UUN3ME2yMlAyPTRzIN88US=>	MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LAMA-84	M1LVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYn4OWloUUN3ME2yMlAzPjh7IN88US=>	NIXRb\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-39	NXTHT255T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\4UY9EUUN3ME2yMlA{OjhizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LOXIMVI	MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDFZopKSzVyPUKuNFQxQDRizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NH-12	NHT6SHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJwMEW0NlQh\|ryP	NVfYfmFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1048	NImyd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHiTWM2OD1{LkGwOVIh\|ryP	NYT2SFQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KS-1	NFji[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXJNGZKSzVyPUKuNVExODFizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-N87	M3TZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j0dGlEPTB;Mj6xN\|M5PCEQvF2=	NEfHTlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CHP-212	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nsPGlEPTB;Mj6xPFQ1OiEQvF2=	Ml7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCC1419	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPP[YpzUUN3ME2yMlIyOTF3IN88US=>	M{L3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ES1	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnUTGNKSzVyPUKuNlE{OjZizszN	M1HMT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H2030	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJwMkSxNlMh\|ryP	MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EW-22	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;TTWM2OD1{LkK1NFY4KM7:TR?=	NV20eFBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A431	NIK1eGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLLbZI1UUN3ME2yMlI4OzV2IN88US=>	NGnXelM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SF126	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJwM{C2NlUh\|ryP	NIThZ\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SF295	M2r5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLTTJVKSzVyPUKuN\|E2OjRizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
D-502MG	NWeyS\|hET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1SzNGlEPTB;Mj6zNlQ3OSEQvF2=	NYrwWnByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HCC2157	NXft[4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\iUGlEPTB;Mj6zNlkzPyEQvF2=	M331NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
D-283MED	NYHDZ3gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjkTWM2OD1{LkO1PVI3KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SNU-423	NXe1VlRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\3TWM2OD1{LkSwNVcyKM7:TR?=	M2i0[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-LU-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL1UWhZUUN3ME2yMlQ1PTh4IN88US=>	M3fESFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
22RV1	NYjKe3ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELjWGFKSzVyPUKuOFU3OTdizszN	M3XrdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW1088	M4jLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTJwNEmyNVMh\|ryP	M2K2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HT-3	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HnUWlEPTB;Mj60PVI2QSEQvF2=	NWnpRoR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1666	NXnhZVZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTJwNUGxNFQh\|ryP	M2GzdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EM-2	M4n2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTPblY4UUN3ME2yMlUyOTZ7IN88US=>	NV76UphERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SNU-449	NXL3d\|B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPwTWM2OD1{LkW3NFE1KM7:TR?=	Mn;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
786-0	NGC1XYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HDfWlEPTB;Mj61PVI{QCEQvF2=	MkXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SKG-IIIa	NGfPb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGD3UlRKSzVyPUKuOlU6OzlizszN	M3n0WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MEL-HO	NV24UVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJwNke2N\|Qh\|ryP	MnTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LCLC-97TM1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTJwNkmyOlch\|ryP	M2SxcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MKN7	M2m3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXLU4NKSzVyPUKuO\|A4PTRizszN	M2\SPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
5637	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHISlVKSzVyPUKuO\|ExOzVizszN	NV\ORnVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HOP-92	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWn6WWFzUUN3ME2yMlc1PzF5IN88US=>	NWTWSHpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MDA-MB-157	MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{GwNmlEPTB;Mj64NlAzOyEQvF2=	MnPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NB12	M{XJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;XS2lEPTB;Mj64OFkyPCEQvF2=	NV7U[G86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
DMS-273	NYPIW5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3r2OWlEPTB;Mj64OlQ4KM7:TR?=	M17zcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC70	M3vM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nIUmlEPTB;Mj64OlU5QSEQvF2=	NFixZng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
YKG-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXRTWM2OD1\|LkCzO\|g4KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H28	NWnZPW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrKTWM2OD1\|LkC1NlkyKM7:TR?=	M3SwN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HN	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfVb25KSzVyPUOuNFY3OzZizszN	NHHTbnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HT-1080	NXjvbVZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTNwMEi2NFYh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HPAF-II	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XRdmlEPTB;Mz6xNFA3QCEQvF2=	NWnhWVlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
U-2-OS	M4PTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{f3UWlEPTB;Mz6xN\|c5OiEQvF2=	M3;t[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SNU-387	NWnNO4ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HQUmlEPTB;Mz6xOlM3PCEQvF2=	M4DMelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Becker	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTNwMU[4NFgh\|ryP	NX7EPZhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BHY	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHi0WmpKSzVyPUOuNlU2PzFizszN	M1;rZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HTC-C3	NVfwbo81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDnTWM2OD1\|LkK5N\|UzKM7:TR?=	NHe5VVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
M14	MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{CxSWlEPTB;Mz6zNFY3OyEQvF2=	NHrUVnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
COR-L23	NFz0[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXkUJhxUUN3ME2zMlM4Ojd7IN88US=>	MkfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
C32	NIrpZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO5RnFKSzVyPUOuOFE2ODhizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
Mewo	NUfLW3IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfJTWM2OD1\|LkSyNVgzKM7:TR?=	MlXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TE-8	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\DW\|NKSzVyPUOuOFgzPTlizszN	NUfDSnRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RPMI-2650	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnpNHhKSzVyPUOuOlA3OzdizszN	M33lcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
AGS	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFj6V3hKSzVyPUOuOlI1PjRizszN	MnfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MZ2-MEL	M1L4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ftVWlEPTB;Mz62OlE{QCEQvF2=	NUnRV5NDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Calu-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTNwN{GyPFch\|ryP	MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SJSA-1	M1Ps[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHK3OG1KSzVyPUOuO\|E{OTVizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW962	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDJRXMxUUN3ME2zMlczPjN4IN88US=>	NGez[pk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
PC-14	M3LvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTYTWM2OD1\|LkezNlIzKM7:TR?=	NHLIN5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW1573	NGLhVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTNwN{WzOFgh\|ryP	MlXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
769-P	NX\aZ5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PZOGlEPTB;Mz64Nlc1OyEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KNS-62	NGnNdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTNwOUKzN\|gh\|ryP	NGTSfnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H747	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTRwMEW2N\|gh\|ryP	MoTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LN-405	M{ixOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXMOYp[UUN3ME20MlE2PzJ6IN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OVCAR-8	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTRwMkK1OFMh\|ryP	NFS0[2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DMS-114	M1vpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rDWmlEPTB;ND6yN\|g6OSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2126	NUDlSFIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j3TGlEPTB;ND6yOFU2QCEQvF2=	NFXHPG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TCCSUP	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWOwcGRwUUN3ME20MlI1Pzh6IN88US=>	MlXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SK-N-FI	NGjt[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfEVphKSzVyPUSuNlU{OzJizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCE-4	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTRwMkexPVch\|ryP	Mm\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DK-MG	NVrFXY0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTRwM{CzPUDPxE1?	M1vuXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RO82-W-1	NVG5cJZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTRwM{K1PFQh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A2780	M4LIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYixeXV{UUN3ME20MlM3Pjh{IN88US=>	Mmn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ETK-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni2TWM2OD12LkO3NFUzKM7:TR?=	MmPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
FADU	M{\UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTRwM{e0Olch\|ryP	NXn6[W1bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-12T	NVXLPG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTRwNEG0NVMh\|ryP	M4Dq[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
647-V	M3TDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonZTWM2OD12LkS0NFIzKM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TGBC1TKB	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\1fGlEPTB;ND60OVEyOyEQvF2=	M{fvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LU-99A	M3WxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jyXmlEPTB;ND60OlA3KM7:TR?=	MlWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-33	NHz1T\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjHVZNZUUN3ME20MlUzPDV4IN88US=>	NXHoWZdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LU-134-A	NXz0OHNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rtVWlEPTB;ND61Nlc1PSEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1355	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LldmlEPTB;ND61OVE1PiEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RPMI-7951	NXP6VoROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHCTWM2OD12LkW3NFAzKM7:TR?=	MkLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TE-1	NVXGelhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zJUmlEPTB;ND62OlE1OyEQvF2=	NVP2ZnU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OE33	M3zqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7ITWM2OD12LkewOVEyKM7:TR?=	NUnu[YlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-51	NHzDN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTRwN{GwPFIh\|ryP	NWHxcGN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW1783	NX2wO3E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3O1OGlEPTB;ND63OVMxQCEQvF2=	NXTWbmhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BT-474	NVK3d4syT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTYTWM2OD12Lke2N\|g1KM7:TR?=	NVPEd25pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-520	NIjPTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrNd2tlUUN3ME20Mlg4Ozl{IN88US=>	NYK3W\|NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
8-MG-BA	M4Lqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TlO2lEPTB;ND64PFU2PyEQvF2=	M1TpWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
IA-LM	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HkO2lEPTB;ND65PVQ{PSEQvF2=	NX;4d4Y5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW954	NH\2SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkS4TWM2OD12Lkm5OFQ{KM7:TR?=	Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RPMI-8226	NUDOb5hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;w[mlEPTB;NT6wOVQ3OSEQvF2=	NHqw[Gk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MKN1	NYPCfJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTVwMEe5Nlch\|ryP	NU[wbXRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A375	M1HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrrTWM2OD13LkC5NlU3KM7:TR?=	M1fidlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
8305C	NGW3eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;wTWlEPTB;NT6wPVg5PyEQvF2=	M2SwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-62	M3vLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zHWGlEPTB;NT6xPFI2QSEQvF2=	NILqZ4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NB10	NH;EfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zmfGlEPTB;NT6yNlc1PCEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OC-314	NGDTRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTVwM{e0OFQh\|ryP	Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PSN1	NFyxU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrMOo9GUUN3ME21MlM5Ojh4IN88US=>	M3vkfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
GR-ST	NGr0OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PNbmlEPTB;NT6zPFMzOiEQvF2=	NVXC[ZRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnqwTWM2OD13LkSwNUDPxE1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1092	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXUdHVUUUN3ME21MlQyOTR6IN88US=>	M3fsWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SCC-4	M4fqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnPSXhKSzVyPUWuOFE{PTVizszN	Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TE-6	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fTUGlEPTB;NT60NVgyPiEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DOHH-2	MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PuWWlEPTB;NT60NlI1QCEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW684	NYfGeWY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjDZ2pKSzVyPUWuOlY{QDVizszN	M2nsR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CP50-MEL-B	M2\2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXxb3BKSzVyPUWuOlg3QDRizszN	MnnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
UM-UC-3	M1zu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWW4UZdGUUN3ME21MlczOjNzIN88US=>	Mo\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LC-2-ad	M3z2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrPfI5KSzVyPUWuO\|gzPTFizszN	MkDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PC-3	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVG1NZFrUUN3ME21MlkyPjF3IN88US=>	M4jlN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAN	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmT4TWM2OD13LkmyPFIh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ESS-1	NFrK[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfpTWM2OD13Lkm3PFY6KM7:TR?=	NHP4dVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ATN-1	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVG1dGRQUUN3ME22MlA2PTZ6IN88US=>	NHTtdms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BxPC-3	M{TpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLtTWM2OD14LkC4NlE6KM7:TR?=	MlzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KYSE-150	NVzwV\|BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnCfI91UUN3ME22MlEzPDd4IN88US=>	MmSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RPMI-8866	M3nHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvhSmZKSzVyPU[uNVkyPjNizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW780	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XCNGlEPTB;Nj6yNFQzKM7:TR?=	MlHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
A388	NIH0VoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7STWM2OD14LkKzNVE2KM7:TR?=	NVmzc2t2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1437	M33BV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\4dmlEPTB;Nj6yOFA4OyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1755	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHhTWM2OD14LkO2OlEzKM7:TR?=	NITMTIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LS-123	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTqTWM2OD14LkSwOVIyKM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CaR-1	NHfx[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmf4TWM2OD14LkS2N\|c{KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RT-112	NUHsWpBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTZwNkCzN\|gh\|ryP	M1LzNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CGT	M1vETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTZwN{O2PFEh\|ryP	M{LuU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW626	M1nJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUD6XHBlUUN3ME22Mlc{QTR4IN88US=>	M3u1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
AsPC-1	NX;qW292T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\scGlEPTB;Nj63OFUxPyEQvF2=	NXT1V5dxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SBC-5	NHfiTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XtcGlEPTB;Nj65O\|I6PyEQvF2=	NUD4dHJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SF539	NXvSOJRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWr1UVZQUUN3ME22Mlk6OzN\|IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TI-73	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHe0SopKSzVyPUeuNFYzQDVizszN	M2\jb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MHH-ES-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPSTYFKSzVyPUeuNFc4PjJizszN	M3exVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KYSE-510	MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTdwMEi0N\|Ih\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
EW-1	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe1NZhZUUN3ME23MlM3QTl4IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SK-OV-3	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPLWGFKUUN3ME23MlM6PDN{IN88US=>	MnzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MC-IXC	M3TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkmxTWM2OD15LkSxPVczKM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HSC-2	NYm5eYNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlWzTWM2OD15LkSyO\|A2KM7:TR?=	NIjZVlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H2342	NG\BPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\KNJBKSzVyPUeuOVE1QSEQvF2=	MlT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1792	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEWxcZJKSzVyPUeuOVE4OTFizszN	MkXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HT-1376	NEjjS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHNOIdGUUN3ME23Mlg4Pzd6IN88US=>	NYe5[ms6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EW-13	MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\lXWlEPTB;Nz64PVk4PyEQvF2=	M4\kflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
no-11	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLqelBIUUN3ME23MlkxOTd2IN88US=>	NF:wUng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
Daoy	MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTdwOUSzNlEh\|ryP	M2LlNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
COLO-800	NWHlfHJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn61TWM2OD16LkC0NVYzKM7:TR?=	NHruWHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GB-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfBUmlTUUN3ME24MlA3PTZ3IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SJRH30	NIL0XJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRThwMUW4O\|gh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2291	M1jEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33KTWlEPTB;OD6yPVE5PyEQvF2=	M{fCU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
J82	MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRThwMkm0PVEh\|ryP	NU\XNIpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H596	NUPxSWJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;sTWM2OD16LkOxOFU{KM7:TR?=	NHzRWVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RERF-LC-MS	MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfsTWM2OD16LkO0PFU3KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RH-18	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRThwM{WwOFYh\|ryP	M1jUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW48	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRThwNUm0OVMh\|ryP	NULQdZkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RD	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRThwNUmzPVEh\|ryP	MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MS-1	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRThwNkGzPFch\|ryP	NHXWXXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ES6	NUnORYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRThwN{OxNVkh\|ryP	NVrtfpBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TE-12	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfSTWM2OD16Lke3OVA2KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DBTRG-05MG	NInWT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X6fmlEPTB;OD65NVIyPyEQvF2=	Mm\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KINGS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHH2cHhKSzVyPUiuPVI6OzhizszN	NV73fHM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HLE	M{e3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M320SmlEPTB;OD65N\|c5PSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MHH-NB-11	M3T3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILQOopKSzVyPUmuNFE5OzlizszN	NXLYRWVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
U-87-MG	M2HheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LNN2lEPTB;OT6yOFMzOSEQvF2=	M{nheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MN-60	NI[xW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTlwMkS1OFIh\|ryP	MmTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SAS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXIfFVkUUN3ME25MlI2PThzIN88US=>	NVzVWWpORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H446	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnqzTWM2OD17LkO2NUDPxE1?	M1va[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
C-33-A	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnmPWU1UUN3ME25MlQ{QTh6IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RXF393	M1u5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF2wenVKSzVyPUmuOFcxODJizszN	NYrHdnpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CGTH-W-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor4TWM2OD17LkS5N\|g1KM7:TR?=	MoLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RCM-1	M4LZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnX[I5nUUN3ME25MlY{QDBzIN88US=>	NXTR[JVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SN12C	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjr[3ZKSzVyPUmuOlU{OzhizszN	NEjZdI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KLE	MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1v3SWlEPTB;OT63NFAxQSEQvF2=	NGD0[pU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EFO-21	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TtO2lEPTB;OT63O\|M5OiEQvF2=	NHfNOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KYSE-70	NXjaZWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTlwOEiwNVEh\|ryP	NH\sc4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
D-247MG	NGnx[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvYUJhKSzVyPUGwMlA2PjhizszN	M37XNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MPP-89	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfoXHg4UUN3ME2xNE4xQTR4IN88US=>	Mof4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RVH-421	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\0VWlEPTB;MUCuNVUxPSEQvF2=	M4r3OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H460	NUK4dFVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XxNWlEPTB;MUCuNlgxPiEQvF2=	M3y1PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NOMO-1	NInYeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTFyLkO1N\|Ih\|ryP	NWnoOJlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
DEL	NIXw[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nH[WlEPTB;MUCuN\|c6PCEQvF2=	NVX5R3JRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HT55	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXJepVKSzVyPUGwMlYzODVizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MC116	NFfYZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTlW3JKSzVyPUGwMlY3PTVizszN	NGDOOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BB30-HNC	MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrCPJVTUUN3ME2xNE43PjlizszN	Mo\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DJM-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\BTWM2OD1zMD62PVQ6KM7:TR?=	NG\WZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ZR-75-30	M2q3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jBN2lEPTB;MUCuPVQ1OSEQvF2=	M17KblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
U-118-MG	NG\xNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\jTWM2OD1zMD65PFk3KM7:TR?=	NXm5eJFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MSTO-211H	MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPYVohKSzVyPUGxMlA4OTZizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW837	M2fqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHJTWM2OD1zMT6wPVQ6KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HuCCT1	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTFzLkGyPFEh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RCC10RGB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\BTWM2OD1zMT6xN\|Uh\|ryP	NWrTSXY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NMC-G1	NVjvcYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV36cVRKUUN3ME2xNU4yPDl\|IN88US=>	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H650	MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvLTWM2OD1zMT6zO\|k1KM7:TR?=	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HEC-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPDN2pPUUN3ME2xNU41OzJ6IN88US=>	Mny1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DU-4475	M4Da[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTFzLkezPVMh\|ryP	MnvYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DSH1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTFzLke2NFYh\|ryP	NE\QdHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HCC1569	NUXEbFluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3z5[WlEPTB;MUGuO\|Y4QCEQvF2=	M{m2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC1187	M2TVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nmeWlEPTB;MUGuPFU5QCEQvF2=	NY\vbGVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EW-11	NFX5NZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fmd2lEPTB;MUGuPVQ4PCEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LB2518-MEL	MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nZVGlEPTB;MUKuNFU6KM7:TR?=	MmTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KALS-1	M2G5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mln3TWM2OD1zMj64OVU{KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
8505C	NYfF[FVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi2W25zUUN3ME2xNk45QDVizszN	NF6zc4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-N-DZ	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHLTWM2OD1zMz6wOFU{KM7:TR?=	NYXDeGRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CHP-134	NGG3[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTnNo1zUUN3ME2xN{4yOTV6IN88US=>	MlHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCE-T	M1PHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF\|LkKzOlQh\|ryP	M{exd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LB-831-BLC	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nBU2lEPTB;MUOuOlI1PiEQvF2=	MkLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OVCAR-4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzubYs6UUN3ME2xN{43PTJ2IN88US=>	NWD5ZmpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW756	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTF\|LkeyOFYh\|ryP	NWPlPYZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OCUB-M	M{f6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjUWFBKSzVyPUGzMlgyPTZizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW982	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2noWmlEPTB;MUOuPFI4PiEQvF2=	M2XwUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
DB	M1nUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjVcWpyUUN3ME2xN{45Ozh2IN88US=>	NHjLO4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
H-EMC-SS	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjv[FJKSzVyPUGzMlkyOzlizszN	NXy5fpBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
VMRC-RCZ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{WxUmlEPTB;MUSuNFAyPSEQvF2=	NGX2bHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAKI-1	NF;TXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXQTWM2OD1zND6wNVMzKM7:TR?=	MkfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GI-1	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XLcGlEPTB;MUSuNFY2QCEQvF2=	NUTlU3ZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Ca9-22	MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13MPWlEPTB;MUSuOlA2PCEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TE-5	NHnBWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjHS5VKSzVyPUG0MlczODhizszN	M{\4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EFO-27	Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPhTWM2OD1zND63OlIzKM7:TR?=	M4KwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-72	M1PiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIqxVXdKSzVyPUG0Mlc4QDNizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GP5d	NGS1XVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmr6TWM2OD1zNT6wOFc1KM7:TR?=	NGLoeG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAS-1	M3vaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\LTWM2OD1zNT6wOlYh\|ryP	M1PpelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A2058	MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPqR4s6UUN3ME2xOU42PjN6IN88US=>	MmDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PANC-08-13	MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTF3Lk[4OVkh\|ryP	M1:0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Detroit562	NXvkSItxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1m4OWlEPTB;MUWuPVE{QSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PANC-10-05	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTF4LkC4NlEh\|ryP	NVLMd2FDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KOSC-2	NWftVGF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1y3N2lEPTB;MU[uNVEzPSEQvF2=	NVT6e4FSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
GT3TKB	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFq2e4VKSzVyPUG2MlE6QDFizszN	NHz1N\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KM-H2	NYj1Z3RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jqWGlEPTB;MU[uN\|Y1PiEQvF2=	NXT1WpdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LB771-HNC	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTF4LkS0NlIh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SF268	M1vnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPCTWM2OD1zNj60OVIh\|ryP	MlX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OE19	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nKO2lEPTB;MU[uOVI1KM7:TR?=	NFj1Tm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MLMA	M{foV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\lTWM2OD1zNj61OVcyKM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MDA-MB-231	NVPzNlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPLdplKSzVyPUG2MlcyOzZizszN	M1zQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
TGW	NWThUXQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPyZ2FKSzVyPUG2MlgyODJizszN	NHLUeW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MDA-MB-453	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjDNVJKSzVyPUG3MlAxODNizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SNU-C2B	M3HySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrVR4c3UUN3ME2xO{4xOjN5IN88US=>	M2jVOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A427	MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\wTWM2OD1zNz6yN\|M1KM7:TR?=	MmjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SK-MEL-2	Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjITWM2OD1zNz6zNlE{KM7:TR?=	Mo[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KURAMOCHI	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHKTWM2OD1zNz6zPFk4KM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
IST-MEL1	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7DPWRpUUN3ME2xO{46OTh{IN88US=>	M1;0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1793	NVvseYdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3kUYFKSzVyPUG4MlE2QDFizszN	MmjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCC1395	M{LiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vvNWlEPTB;MUiuOVYyOSEQvF2=	NGKwOWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NUGC-3	M4ewV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjQTXR3UUN3ME2xPE43PTh2IN88US=>	M1i4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BB65-RCC	NGHIZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vxbGlEPTB;MUiuOlY6KM7:TR?=	NHfhZYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RMG-I	NIiwUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTF6LkezPFIh\|ryP	NEeycmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LS-513	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlSwTWM2OD1zOD65NlI5KM7:TR?=	M1vzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MFM-223	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTF7LkC3NVYh\|ryP	NUG4dnYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H727	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;vUmlEPTB;MUmuN\|I6PSEQvF2=	NHPmSIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KP-4	NHS1WJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjWTWM2OD1zOT64OVMyKM7:TR?=	MnrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NB13	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTF7Lki4N\|kh\|ryP	M4[wV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
UACC-893	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;zWo9zUUN3ME2xPU46PzV5IN88US=>	MmCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HT-1197	NWDDNWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX3TWM2OD1{MD6yPVU5KM7:TR?=	NXu5WXhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H2029	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;EfVlSUUN3ME2yNE4{OjZ4IN88US=>	NETEO209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GI-ME-N	NH30XZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHsTWM2OD1{MD6zN\|c{KM7:TR?=	M4m2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
OVCAR-3	Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXqTWM2OD1{MD61PFIzKM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HD-MY-Z	M{fJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXj2ZWRFUUN3ME2yNU4{Pjl4IN88US=>	NXO3dVcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NTERA-S-cl-D1	MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvmNIVTUUN3ME2yNU43PzJ{IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SCH	NGTOR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTJ{LkS5OkDPxE1?	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KARPAS-299	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTxU3ZEUUN3ME2yN{4{QDh5IN88US=>	NVPlU4FYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1650	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJ\|LkmyOFEh\|ryP	NWjJcIhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ACHN	NFj2NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJ2LkS2OVYh\|ryP	NXGwZYdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
M059J	M1zCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTJ2LkW2N\|Qh\|ryP	M2rVT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
AM-38	NH;jSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDxSnRKSzVyPUK1MlQ5OSEQvF2=	M3PpcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KG-1	M3XRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjUTWM2OD1{NT61OFk1KM7:TR?=	M1zJbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
COLO-824	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTGdIxKSzVyPUK1MlU2QTlizszN	M4nM[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1155	M4DycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGmzWVlKSzVyPUK1MlU5PDdizszN	M1\oUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H441	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDKTWM2OD1{NT63OFY2KM7:TR?=	NH;vWmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
J-RT3-T3-5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\BUWlEPTB;Mk[uN\|AzPyEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
JEG-3	M3rLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJ4Lk[4NFUh\|ryP	M{W0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RKO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJ4Lke2N\|Ih\|ryP	MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-85-1	NUf2PVNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTJ5LkKxNVgh\|ryP	NFrqc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-120	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTJ5Lk[5NVQh\|ryP	NE\pUW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H2452	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjVVIhKSzVyPUK3Mlc4OTZizszN	NYi2NFliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1395	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjV[oRKSzVyPUK3Mlc5OzNizszN	M2O4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KYSE-450	NIG1bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfDOJNrUUN3ME2yO{46QDZ{IN88US=>	NVi5OohyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
S-117	NWXMU\|A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHxbYRXUUN3ME2yPU4{QDV5IN88US=>	M2W2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW13	NW\uNmdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\scpBKSzVyPUK5Mlg2OTlizszN	NF;XNJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ES3	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjRcodKSzVyPUOwMlM4OzNizszN	MkLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCT-116	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonCTWM2OD1\|MD61OVU1KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1693	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTqTWM2OD1\|MD61PVQzKM7:TR?=	NHK1Z3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
VM-CUB-1	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HxV2lEPTB;M{CuOlQyOyEQvF2=	MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2170	NXvxTlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEK0cZpKSzVyPUOxMlU4QDRizszN	M4LPVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ALL-PO	M2HiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTNzLki0Nlgh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H661	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHiyPGxKSzVyPUOyMlA3OjNizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2347	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPxeVJ[UUN3ME2zNk41QDN5IN88US=>	NHu1bXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
FTC-133	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTN{LkewOkDPxE1?	NFy2dJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
COLO-829	NHG4fJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7sTWM2OD1\|Mz6zOFY4KM7:TR?=	NIjsUYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GOTO	M2frSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vPWGlEPTB;M{OuOVI2QCEQvF2=	NUjJNpl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
YAPC	M4CzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLTVYJKSzVyPUOzMlgyPTlizszN	MnXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LCLC-103H	NWLMbIViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjlVGdvUUN3ME2zOE4yPjJ2IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SiHa	NVjwdWlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vRXWlEPTB;M{SuN\|gyPyEQvF2=	NXThRYdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LK-2	NELZXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjYSY5KSzVyPUO0MlU4ODhizszN	NE\nUJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KP-N-YS	M2nLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXEOmZKSzVyPUO0MlczODJizszN	M2HQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-SNU-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHmRoNKSzVyPUO1MlE4QSEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KNS-81-FD	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nkTGlEPTB;M{WuOlY{KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SCC-9	NV;ycmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEP3S3VKSzVyPUO2MlcyPDZizszN	NWfiRmdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SH-4	NFXxcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zCV2lEPTB;M{[uO\|Mh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCC-1954	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTN5LkK3Nlkh\|ryP	NILEfpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BALL-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrUSFBJUUN3ME2zO{42OzF4IN88US=>	NEe4Vos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BE-13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTN5LkewNVgh\|ryP	M4jvSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
COLO-678	NFjiSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTN5Lkm0N\|ch\|ryP	M1e1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-MEL-3	M{\Cfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTN6LkKzPVch\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OAW-28	NUH1cIg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\TOmlEPTB;M{iuOlM6KM7:TR?=	MnvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAMA-1	NUDFfWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HyTmlEPTB;M{iuPVY6OSEQvF2=	NWLtc2J6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
C2BBe1	M4LRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXaPXdYUUN3ME2zPU45OThizszN	Mmq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
A3-KAW	Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\wT2lEPTB;NECuN\|Y3OSEQvF2=	NH\3W2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-MEL-24	NVexU2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\GTWM2OD12MD61PVMyKM7:TR?=	M3i4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KYSE-140	M4rLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGCze4dKSzVyPUSwMlcyPjVizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MOLT-16	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rlWmlEPTB;NEGuNVU{PiEQvF2=	M4f0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CFPAC-1	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HOOGlEPTB;NEKuOVIyOSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NB14	NWXxVmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TWc2lEPTB;NEKuO\|AzPyEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
COLO-792	NYjHeG9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnQU4tHUUN3ME20Nk45QTZzIN88US=>	M3zERVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RH-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvYfZp{UUN3ME20N{41QDN4IN88US=>	NITPVIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H522	NFTDS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{i3Z2lEPTB;NESuN\|U3QCEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
Ca-Ski	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjhO3dKSzVyPUS0MlgyOTRizszN	M1mzN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KGN	Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2f5W2lEPTB;NEiuN\|A3OyEQvF2=	MmXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
UACC-62	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3m0bmlEPTB;NEiuOFA4OiEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H358	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlX6TWM2OD12OT6zNFE5KM7:TR?=	NHPKcW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LS-411N	NXnQWZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWK5eW1qUUN3ME20PU4{OTF6IN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
IST-MES1	NEmxN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\LOFlKSzVyPUS5MlU3OjVizszN	MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RG7321
Smiles	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)